• History of Venous Thromboembolism
  Arthur A. Sasahara, MD
  
• Epidemiology of VTE
  Sam Schulman, MD

• Genetics of VTE
  Paul M Ridker, MD, MPH
  
• Diagnosis of DVT
  Marie Gerhard-Herman, MD

• Diagnosis of Pulmonary Embolism
  Henri Bounameaux, MD
  
• Hypercoagulability
  Kenneth Bauer, MD

• VTE Treatment: Conventional Pharmacotherapy
  C. Gregory Elliott, MD

• Heparin-Induced Thrombocytopenia and Direct Thrombin Inhibitors
  Steve Baroletti, PharmD, MBA
  
• VTE: Pregnancy, Birth Control, and Hormone Replacement Therapy
  Samuel Z. Goldhaber, MD
  
• VTE in Children and Adolescents
  Cathy G. Rosenfield, MD

• Cancer and Thrombosis
  Craig M. Kessler, MD, MACP
  
• DVT Thrombolysis
  Suresh Vedantham, MD
  
• Massive Pulmonary Embolism: Thrombolysis and Surgery
  Samuel Z. Goldhaber, MD

• Catheter Pulmonary Embolectomy
  Frederic S. Resnic, MD, MSc
  

• Chronic Thromboembolic Pulmonary Hypertension
  Michael J. Landzberg, MD

• Atherothrombosis
  Peter Libby, MD
  
• Inflammation and the JUPITER Trial
  Paul M Ridker, MD, MPH
  
• Acute Coronary Syndromes
  Elliott M. Antman, MD
  
• ACE Inhibitors and Angiotensin Receptor Blockade
  Marc A. Pfeffer, MD, PhD

• Antiplatelet Therapy
  Stephen D. Wiviott, MD
  
• Peripheral Vascular Disease
  Marie Gerhard-Herman, MD
  
• Coronary Artery Stents: Drug-Eluting versus Bare Metal
  Laura Mauri, MD, MSc
  
• Idiopathic Pulmonary Hypertension
  Michael J. Landzberg, MD

• VTE Prophylaxis
  Samuel Z. Goldhaber, MD

• Vascular Medicine Quiz
  Joshua A. Beckman, MD
  
• Novel Anticoagulants
  Jeffrey Weitz, MD

• Optimal Duration of Anticoagulation for VTE
  Clive Kearon, MD
  
• IVC Filters
  Piotr Sobieszczyk, MD

Samuel Z. Goldhaber, MD

Dr. Goldhaber is Professor of Medicine at Harvard Medical School and is a Senior Staff Member of the Cardiovascular Medicine Division at Brigham and Women’s Hospital (BWH). He is Director of the BWH Venous Thromboembolism Research Group and serves as Principal Investigator of a broad range of randomized clinical trials and observational studies related to the prevention, treatment, and epidemiology of venous thromboembolism.

Dr. Goldhaber has authored more than 400 publications. The March 10, 2005, New England Journal of Medicine published his large clinical trial that described a new method using electronic, computerized alerts to enhance venous thromboembolism prophylaxis. This intervention reduced symptomatic DVT and PE by 41%, without an increase in bleeding complications.

In 2008, the National Heart Lung and Blood Institute appointed him to serve on the Steering Committee of its new multicenter trial: “A Randomized Controlled Clinical Trial of Clarification of Optimal Anticoagulation through Genetics.” Dr. Goldhaber also serves as Chair of the Steering Committee of the investigator-initiated, NHLBI-sponsored “ATTRACT Trial”.

Dr. Goldhaber is President and one of four Founding Directors of the nonprofit North American Thrombosis Forum (www.NATFonline.org).

Paul M Ridker, MD, MPH

Dr. Ridker is the Eugene Braunwald Professor of Medicine at the Harvard Medical School and directs the Center for Cardiovascular Disease Prevention at the Brigham and Women’s Hospital in Boston which focuses on molecular and genetic epidemiology of cardiovascular diseases.

A graduate of Brown University, Harvard Medical School, and Harvard School of Public Health, Dr. Ridker’s research brings together classical tools of population based epidemiology with emerging genetic and molecular techniques designed to improve prediction and prevention of heart attack and stroke. Dr. Ridker’s research efforts are primarily supported by grants from the National Heart, Lung, and Blood Institute, the Leducq Foundation, and the Donald W. Reynolds Foundation.

Dr. Ridker has been the recipient of multiple awards including an Established Investigator Award (American Heart Association), a Distinguished Investigator Award (Doris Duke Foundation), and elected membership to the American Society for Clinical Investigation, the American Epidemiological Society, and the American Association of Physicians. Citing his pioneering work on inflammation, C-reactive protein (CRP), and heart disease, Time Magazine honored Dr. Ridker as one of America’s Ten Best Researchers in Science and Medicine in 2001 and as one of the “Time 100 Most Influential” in 2004.

In 2008, Dr. Ridker presented results of the multi-national landmark JUPITER trial demonstrating the life-saving benefits of statin therapy among those with low cholesterol but elevated CRP levels, a prevention strategy that will result in 250,000 fewer heart attacks, strokes, and cardiovascular deaths in the United States alone.